溶瘤腺病毒靶向癌症治疗的临床研究进展

中国生物工程杂志

2013, Vol. 33

Issue (12): 105-113

综述

溶瘤腺病毒靶向癌症治疗的临床研究进展

周立, 何婉婉, 朱桢楠, 杨远勤, 赵红芳, 马步云, 王毅刚

浙江理工大学生命科学学院新元医学与生物技术研究所杭州 310018

The Clinical Research Progress for Oncolytic Adenovirus Targeting Cancer Therapy

ZHOU Li, HE Wan-wan, ZHU Zhen-nan, YANG Yuan-qin, ZHAO Hong-fang, MA Bu-yun, WANG Yi-gang

Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China

全文: PDF(618 KB) HTML

摘要： 自上世纪 50 年代，腺病毒的发现并成功分离后，生物学家对溶瘤腺病毒进行了广泛的研究。与其他病毒相比，溶瘤腺病毒能够特异性地感染肿瘤细胞并在肿瘤细胞中完成感染-复制周期，从而特异性地杀伤和裂解肿瘤细胞但不损伤其他正常细胞和组织，因此成为目前最具研究前景的抗肿瘤药物之一。然而，在临床基因治疗过程中，腺病毒载体存在缺乏组织或细胞特异性，靶向细胞的基因转染效率较低以及缺乏一定的安全性等问题。因此，提高重组腺病毒的靶向性对于癌症基因治疗成功与否极为关键。据相关研究表明，目前溶瘤腺病毒作为癌症基因治疗载体已经进入相关临床试验阶段，并涉及多种癌症，而且也显示了很好的临床应用前景。对溶瘤腺病毒的种类、癌症靶向策略及临床研究等进行了综述。

关键词： 溶瘤腺病毒; 靶向策略; 临床研究

Abstract: Adenovirus has been discovered and successfully isolated since the 1950s,then biologists conduct extensive researches on oncolytic adenovirus.Compared to other viruses,oncolytic adenovirus could infect tumor cells specifically and accomplish an infection-replication cycle in tumor cells,which can specifically kill and destroy cancer cells,but not damage normal cells or tissues.It has become one of the most promising antineoplastic medicines. However,at the process of clinical gene therapy, adenovirus vectors present the problems that lacking tissues or cells specificity,low genetic transfection efficiency of targeting cells and the lack of certain safety.Therefore,it is rather crucial to improve the targeting ability of recombinant adenovirus for cancer gene therapy.According to relevant studies, a variety of oncolytic adenoviruses as vectors of cancer gene for therapy have entered into related clinical trials involving different kinds of cancers,which shows admirable clinical application. It is mainly to focus on the oncolytic adenovirus types, cancer targeting strategies and clinical studies.

Key words: Oncolytic adenovirus Targeting strategy Clinical study

收稿日期: 2013-10-17 出版日期: 2013-12-25

ZTFLH:

Q819

基金资助: 国家自然科学基金（81272687）；国家“863”计划（2012AA020806）；浙江省自然科学基金（Z13H160020）资助项目

通讯作者: 王毅刚，E-mail：wangyigang43@163.com E-mail: wangyigang43@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周立
	何婉婉
	朱桢楠
	杨远勤
	赵红芳
	马步云
	王毅刚

引用本文:

周立, 何婉婉, 朱桢楠, 杨远勤, 赵红芳, 马步云, 王毅刚. 溶瘤腺病毒靶向癌症治疗的临床研究进展[J]. 中国生物工程杂志, 2013, 33(12): 105-113.

ZHOU Li, HE Wan-wan, ZHU Zhen-nan, YANG Yuan-qin, ZHAO Hong-fang, MA Bu-yun, WANG Yi-gang. The Clinical Research Progress for Oncolytic Adenovirus Targeting Cancer Therapy. China Biotechnology, 2013, 33(12): 105-113.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/ 或 https://manu60.magtech.com.cn/biotech/CN/Y2013/V33/I12/105

[1] Smith R R, Huebner R J, Rowe W P, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer, 1956, 9(6): 1211-1218.
[2] Southam C M. Division of microbiology: present status of oncolytic virus studies. Transactions of the New York Academy of Sciences, 1960, 22(8 Series Ⅱ): 657-673.
[3] 胡泽斌. 溶瘤腺病毒载体系统的构建及其功能研究. 中国人民解放军军事医学科学院, 2008. Hu Z B.Construction and function study of oncolytic adenovirus vector system, the Academy of Military Medical Sciences of the Chinese PLA, 2008.
[4] 蒋泓, 刘芳, 严爱芬, 等. 溶瘤病毒的肿瘤治疗作用研究. 佛山科学技术学院学报 (自然科学版), 2013, 31(2):1-6. Jiang H, Liu Fang, Yan A F, et al.The application of oncolytic virus to cancer therapy.Journal of Foshan University(Natural Science Edition), 2013, 31(2):1-6.
[5] Liu X, Cao X, Wei R, et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Terapy, 2011, 19(1): 49-57.
[6] Ranki T, Kanerva A, Ristimki A, et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5. pk7-Δ24, for the treatment of advanced breast cancer. Gene Therapy, 2006, 14(1): 58-67.
[7] 徐凯, 诸琦. 溶瘤病毒的临床应用. 生物医学工程与临床, 2008, 12(4): 347-350. Xu K, Zhu Q.Clinical application of oncolytic virus.Biomedical Engineering and Clinical Medicine, 2008, 12(4): 347-350.
[8] 谭晓华. 溶瘤腺病毒肿瘤靶向治疗: 从实验室到临床. 中国肿瘤生物治疗杂志, 2012, 19(006): 569-576. Tan X H.Oncolytic adenovirus for targeted cancer therapy:from laboratory to the clinic.Chinese Journal of Cancer Biotherapy, 2012, 19(006): 569-576.
[9] 王毅刚, 黄芳, 蔡荣, 等. 腺相关病毒载体的靶向策略探讨. 科学通报, 2007, 52(10): 1107-1115. Wang Y G, Huang F, Cai R, et al.A discussion on adenovirus-associated virus vector.Chinese Science Bulletion, 2007, 52(10): 1107-1115.
[10] Li Y, Idamakanti N, Arroyo T, et al. Dual promoter-controlled on-colytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.Clin Cancer Research, 2005, 11(24 Pt 1): 8845-8855.
[11] Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene, 2004, 23(2): 457-464.
[12] Kamizono J, Nagano S, Murofushi Y, et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Research, 2005, 65(12): 5284-5291.
[13] Tiemann K, Rossi J J. RNAi‐based therapeutics–current status, challenges and prospects. EMBO Molecular Medicine, 2009, 1(3): 142-151.
[14] 仲苏阳. 靶向性基因-病毒疗法联合化学药物治疗肿瘤的研究. 浙江理工大学, 2008. Zhong S Y.Combination of targeting gene-virotherapy and chemotherapy.Zhejiang Sci-Tech University, 2008.
[15] Pilankatta R, Chawla T, Khanna N, et al. The prevalence of anti-bodies to adenovirus serotype 5 in an adult indian population andimplications for adenovirus vector vaccines.J Med Virol, 2010, 82(3): 407-414.
[16] Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.Mol Ther, 2009, 17(10): 1667-1676.
[17] Brummelkam PT R, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells.Science, 2002, 296(5567): 550-553.
[18] Bessard A, Frémin C, Ezan F, et al. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene, 2008, 27(40): 5315-5325.
[19] Wang Y H, Liu S, Zhang G, et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo.Breast Cancer Res, 2005, 7(2):220-228.
[20] Chu L, Gu J, Sun L, et al. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther, 2008, 15:484-494.
[21] Zheng J N, Ma T X, Cao J Y, et al. Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sciences, 2006, 78(7): 724-729.
[22] 陈家存, 郑骏年, 毛立军, 等. 表达 Ki67 基因小干扰 RNA 的选择性增殖溶瘤腺病毒的构建. 中华实验外科杂志, 2006, 23(7): 849-852. Cheng J C, Zheng J N, Mao L J, et al.Construction and identification of replication selective oncolytic adenovirus expressing short interferenee RNA targeting Ki67gene.Chinese Journal of Experimental Surgery, 2006, 23(7): 849-852.
[23] 潘秋卫, 蔡荣, 刘新垣, 等. 肿瘤基因治疗新策略——RNA 干扰. 科学通报, 2006, 51(9): 993-997. Pan Q W, Cai R, Liu X Y, et al.A novel strategy in cancer gene therapy:RNAi.Chinese Science Bulletin, 2006, 51(9): 993-997.
[24] 王卫芸, 顾锦法, 戴平, 等. 双靶向溶瘤腺病毒 MD55 对肿瘤细胞与正常细胞的杀伤作用比较. 细胞生物学杂志, 2008, 30(5): 635-641. Wang W Y, Gu J F, Dai P, et al.Selective cytotoxic effect of dual tumor-targeting oncolytic adenovirus MD55 on tumor and normal cells in vitro.Chinese Journal of Cell Biology, 2008, 30(5): 635-641.
[25] 张唯, 张红锋. 双靶向溶瘤腺病毒对肿瘤细胞及正常细胞的杀伤差异性研究. 华东师范大学学报(自然科学版), 2007, 6:112-119. Zhang W, Zhang H F.Difference of killing effects of dual-targeting oncolytic adenovirus on tumor and normal cells.Journal of East China Normal University(Natural Science), 2007, 6:112-119.
[26] 王娟, 顾锦法, 杨水云, 等. 癌特异性双靶向载体的安全性及其携带基因的杀伤性.癌症, 2006, 25(4): 385-392. Wang J, Gu J F, Yang S Y, et al, Security of dual cancer-specific targeting vector and its cytotoxic effect when harbored.Chinese Journal of Cancer, 2006, 25(4): 385-392.
[27] 曾祯, 刘新垣. 携带TRAIL和IL-24的双基因三靶向溶瘤腺病毒构建及其抗癌效果的研究. 中国科技论文在线, http://www.paper.edu.cn/releasepaper/content/201202-830. Zeng Z, Liu X Y. Triple-regulated oncolytic adenovirus mediates coexpression of TRAIL and IL-24 linked by IETD sequence.Science Paper Online, http://www.paper.edu.cn/releasepaper/content/201202-830.
[28] Liu X R, Cai Y, Cao X, et al. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti‐tumour effect. Journal of Cellular and Molecular Medicine, 2012, 16(6): 1298-1309.
[29] 刘佳, 马蕾娜, 王毅刚, 等. 癌症治疗新思路: 靶向肿瘤干细胞. 科学通报, 2008, 53(9): 1003-1009. Liu J, Ma L N, Wang Y G, et al, Novel strategy in cancer treatment:targeting cancer stem cell. Chinese Science Bulletin, 2008, 53(9): 1003-1009.
[30] 张金龙, 钱海利, 林晨, 等. 肿瘤干细胞靶向治疗研究进展. 中国医药生物技术, 2010, 5: 371-373. Zhang J L, Qiang H L, Lin C, et al. Progression in cancer stem cell targeted therapy.Chinese Medicinal Biotechnology, 2010, 5: 371-373.
[31] Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. Journal of the National Cancer Institute, 2007, 99(18): 1410-1414.
[32] John W, Son L. Gene Therapy Clinical Trials Worldwide:http://www.abedia.com/wiley/vectors.php.
[33] 张璐, 林军, 郑玉果, 等. 病毒与肿瘤发生及治疗的关系. 世界临床药物, 2012, 33(006): 375-379. Zhang L, Lin J, Zheng Y G, et al, Role of virus in the tumor genesis and treatment. World Clinical Drugs, 2012, 33(006): 375-379.
[34] 胡放, 胡晓桦, 余萍, 等. 溶瘤病毒 H101 结合局部加热治疗对转移肿瘤病灶的远端效应. 癌症, 2006, 25(8): 919-924. Hu F, Hu X H, Yu P, et al.Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating.Chinese Journal of Cancer, 2006, 25(8): 919-924.
[35] 施静, 刘燕飞. 特异性溶瘤重组腺病毒 Ⅰ 期临床试验受试者的观察. 上海护理, 2010, 10(003): 66-68. Shi J, Liu Y F. The observation of clinical phase I of specific oncolytic recombinant adenovirus in subjects. Shanghai Nursing, 2010, 10(003): 66-68.
[36] Nie Z L, Pan Y Q, He B S, et al. Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system. Molecular Cancer, 2012, 11(1): 86.
[37] Li Y, Li W G, Zhang J S.Recombinant Ad5 interventional treatment of malignant tumors of route safety study. Shanghai Medical & Pharmaceutical Journal, 2013; 34(1):24-26.
[38] Vh-Koskela M J, Heikkil J E, Hinkkanen A E. Oncolytic viruses in cancer therapy. Cancer Letters, 2007, 254(2): 178-216.
[39] 蒋冠, 刘彦群, 郑骏年. 溶瘤腺病毒联合化疗治疗肿瘤的研究. 国际肿瘤学杂志 ISTIC, 2008, 35(9):647-650. Jiang G, Liu Y Q, Zheng J N.Oncolytic adenouiruses in combination with chemtherapy in tumor therapy. Journal of International Oncology, ISTIC, 2008, 35(9):647-650.
[40] Galanis E, Okuno S H, Nascimento A G, et al.Phase I-Ⅱ trial of ONYX.015 in combination with MAP chemotherapy in patients with advanced sarcomas.Gene Ther, 2005, 12(5):437-445.
[41] Yoon A R, Kim J H, Lee Y S, et al.Markedly enhanced cytolysis byE1 B-19kD deleted oncolytic adenovirus in combination with cisplatin.Hum Gene Ther, 2006, 17(4):379-390.
[42] Qiu S, Ruan H, Pei Z, et al.Combination of targeting gene-virotherapy with 5-FU enhances antitumor efficacy in malignant eoloree-tal carcinoma. J Interferon Cytokine Res, 2004, 24(4):219-230.
[43] Quirin C, Mainka A, Hesse A, et al.Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.Int J Cancer, 2007, 121(12):2801-2807.
[44] 郭科妮, 卓玲燕, 刘涛, 等. 携带 TSLC1 基因的双靶向溶瘤腺病毒联合阿霉素对 SMMC-7721 肝癌细胞的杀伤作用. 中国细胞生物学学报, 2013, 35(3): 282-289. Guo K N, Zhuo L Y, Liu T, et al. Killing effect to hepatoma cell SMMC-7721 by dual-regulated oncolytic adenovirus-mediated TSLC1 combined with adriamycin.Chinese Journal of Cell Biology, 2013, 35(3): 282-289.
[45] Kaliberova L N, Krendelchtchikova V, Harmon D K, et al.CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther, 2009, 16:794-805.
[46] Kangasniemi L, Parviainen S, Pisto T, et al. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. International Journal of Cancer, 2012, 131(1): 253-263.
[47] Song X, Wang H, Jia R, et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. International Journal of Molecular Sciences, 2012, 13(9): 10736-10749.
[48] Small E J, Carducci M A, Burke J M, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther, 2006, 14: 107-117.
[49] Freytag S O, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 2002, 62: 4968-4976.
[50] Russell S J, Peng K W, Bell J C. Oncolytic virotherapy. Nature Biotechnology, 2012, 30(7): 658-670.
[51] Russell W C. Update on adenovirus and its vectors. J Gen Virol, 2000, 81(11): 2573-2604.

[1]	许嘉越,李紫倩,张革. 登革病毒3'UTRΔ30系列疫苗的研究进展[J]. 中国生物工程杂志, 2019, 39(3): 97-104.
[2]	马步云, 何婉婉, 周立, 王毅刚. 癌症靶向基因-病毒ZD55-XAF1抗肝癌移植瘤的生长及其安全性研究[J]. 中国生物工程杂志, 2014, 34(1): 15-20.
[3]	顾江, 邹全明. 治疗耐甲氧西林金黄色葡萄球菌感染的抗体药物[J]. 中国生物工程杂志, 2012, 32(02): 96-99.
[4]	于源, 刘忠荣, 余孝其, 吴洽庆. 基因工程药物研制过程中相关问题探讨[J]. 中国生物工程杂志, 2005, 25(10): 93-97.
[5]	谢建平. 专利(即将)到期生物医药产品的博弈策略[J]. 中国生物工程杂志, 2002, 22(2): 91-92.
[6]	丁锡申. 基因工程药物的审批[J]. 中国生物工程杂志, 1995, 15(5): 5-7.
[7]	邱信芳, 薛京伦. 基因治疗研究的现状和展望[J]. 中国生物工程杂志, 1995, 15(1): 18-21.
[8]	徐家立. 努力增加抗癌药紫杉醇的供给[J]. 中国生物工程杂志, 1992, 12(5): 49-51.
[9]	王彩福, 张健诚, 姚宁, 苏盛. LAK细胞实验室及临床研究的进展[J]. 中国生物工程杂志, 1991, 11(6): 19-22.

Viewed

Full text

Abstract

Cited

Shared

Discussed